光学医学成像设备研发、生产商HistoIndex获得900万新加坡元融资，推动下一阶段扩展-动脉网

HistoIndex Secures SGD9 Million Investment to Drive Next Phase of Expansion

CISION 等信源发布 2025-05-02 10:00



可切换为仅中文







SINGAPORE

新加坡

，

May 1, 2025

2025年5月1日

/PRNewswire/ -- HistoIndex, known for its groundbreaking biophotonic Second Harmonic Generation (SHG) technology and a pioneering leader in Artificial Intelligence (AI) digital pathology for the management of fibrotic diseases, has announced the close of a

/PRNewswire/ -- HistoIndex，以其突破性的生物光子二次谐波生成（SHG）技术而闻名，并且是人工智能（AI）数字病理学在纤维化疾病管理领域的先驱领导者，宣布完成了

S$9 million

900万新元

investment round to support its next phase of expansion. OCBC, the longest established bank in

投资轮次以支持其下一阶段的扩张。华侨银行（OCBC），作为历史最悠久的银行在

Singapore

新加坡

and the second largest financial services group in

以及第二大金融服务集团

Southeast Asia

东南亚

by assets, investing for the first time in a medical technology/healthcare company, leads the round with continued support from two existing shareholders - ZIG Ventures and SEEDS Capital, an investment arm of SG Growth Capital.

通过资产首次投资于一家医疗技术/保健公司，引领了这一轮融资，并得到了现有两个股东的持续支持——ZIG Ventures和SEEDS Capital，后者是SG Growth Capital的投资部门。

Daniel Kwan

丹尼尔·关

, Global Head of the Mezzanine Capital Unit at OCBC, said: 'HistoIndex's groundbreaking technology has revolutionized liver disease diagnostics through cutting-edge AI innovations, and has the potential to enhance global healthcare by enabling precise and personalized patient care. We are proud to support this homegrown MedTech company with its growth plans and international ambitions.'.

华侨银行夹层资本部门全球主管表示：“HistoIndex 的突破性技术通过尖端的人工智能创新彻底改变了肝病诊断，并有潜力通过实现精准和个性化的患者护理来提升全球医疗水平。我们很自豪能够支持这家本土的医疗科技公司实现其成长计划和国际雄心。”

With the increasing demand for routine clinical testing of Metabolic Dysfunction-Associated Steatohepatitis (MASH), particularly in liver biopsy assessment, this investment is focused on 1) expanding HistoIndex-partnered laboratories and operations within the US; and 2) developing next-generation AI-powered SHG digital pathology tests for MASH patients..

随着对代谢功能障碍相关脂肪性肝炎（MASH）常规临床检测需求的增加，尤其是在肝活检评估方面，这项投资的重点是：1）扩大HistoIndex合作的美国实验室和运营；2）开发用于MASH患者的下一代AI驱动的SHG数字病理测试。

In line with this mission, HistoIndex has recently launched its very first Laboratory Developed Test (LDT), FibroSIGHT™ – now available for order in the US.

与此使命一致，HistoIndex最近推出了其首个实验室开发测试（LDT），FibroSIGHT™——现在已在美国接受订购。

FibroSIGHT™

纤维视角™

is designed to empower clinicians with accurate and consistent liver fibrosis assessment

旨在为临床医生提供准确且一致的肝纤维化评估能力

. The first in a pipeline of new product launches reaffirms HistoIndex's commitment to revolutionizing personalized treatment for MASH. By integrating research in pivotal clinical trials with clinical practice, the company is advancing precision medicine with the aim of improving patient outcomes worldwide..

新产品发布的首个项目再次确认了HistoIndex致力于革新MASH的个性化治疗。通过将关键临床试验的研究与临床实践相结合，该公司正在推进精准医疗，旨在改善全球患者的治疗效果。

'This investment plays an enabling role in positioning the company for strategic expansion within the US, while accelerating the adoption of advanced digital pathology solutions poised to transform MASH diagnosis and treatments.' said Dr.

“这项投资在推动公司在美国的战略扩张中发挥了关键作用，同时加速了先进数字病理学解决方案的采用，这些方案将改变MASH的诊断和治疗。” 博士说道。

Gideon Ho

吉迪恩·何

, Chief Executive Officer of HistoIndex.

,HistoIndex首席执行官。

About MASH

关于MASH

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of Metabolic dysfunction-associated steatotic liver disease (MASLD) characterized by steatosis and inflammation, which can lead to fibrosis (scarring), cirrhosis, liver failure, and an increased risk of liver cancer. The presence of ballooned hepatocytes (enlarged and damaged liver cells) is a key feature distinguishing MASH from simple steatosis.

代谢功能障碍相关的脂肪性肝炎（MASH）是代谢功能障碍相关的脂肪肝病（MASLD）的一种进展形式，其特征为脂肪变性和炎症，可能导致纤维化（瘢痕形成）、肝硬化、肝衰竭以及肝癌风险增加。气球样肝细胞（肿大且受损的肝细胞）的存在是区分MASH与单纯性脂肪变性的关键特征。

Pathologist assessments of liver biopsy remain the gold standard for diagnosing and assessing the severity of MASH. Histological categorial scoring systems are often used as surrogate endpoints to evaluate drug efficacy in clinical trials. These endpoints are limited in capturing the complex and heterogeneous nature of the disease.

病理学家对肝脏活检的评估仍然是诊断和评估MASH严重程度的金标准。组织学分类评分系统常被用作替代终点，以评估临床试验中药物的疗效。这些终点在捕捉疾病复杂且异质性的本质方面存在局限性。

As a result, there is a growing need for more accurate and reliable tools, such as AI-based digital pathology solutions, to improve the assessment of treatment response and disease severity in MASH..

因此，对于更准确和可靠的工具的需求日益增长，例如基于人工智能的数字病理学解决方案，以改善对MASH治疗反应和疾病严重程度的评估。

About HistoIndex

关于HistoIndex

Founded in 2010, HistoIndex pioneers in stain-free, fully automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. By combining cutting-edge biophotonic technology with AI-based analysis, HistoIndex provides innovative tools to improve the assessment of fibrosis changes and drug efficacy.

成立于2010年，HistoIndex率先推出了无染色、全自动的成像解决方案，用于可视化和量化生物组织中的纤维化。通过将尖端的生物光子技术与基于人工智能的分析相结合，HistoIndex提供了创新工具，以改进对纤维化变化和药物疗效的评估。

HistoIndex's breakthrough digital pathology solutions are currently used in accelerating clinical research, expediting pharmaceutical drug development, and transforming medical standards..

HistoIndex 的突破性数字病理学解决方案目前正用于加速临床研究、加快药物研发以及改变医学标准。

References:

参考文献：

https://histoindex.com/fibrosight/

SOURCE Histoindex Pte. Ltd.

来源：Histoindex Pte. Ltd.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+